Syros Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.07 million shs
Average Volume1.07 million shs
Market Capitalization$347.64 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Syros Pharmaceuticals logo

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.22 out of 5 stars

Medical Sector

946th out of 2,097 stocks

Pharmaceutical Preparations Industry

458th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

Is Syros Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Syros Pharmaceuticals?

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Syros Pharmaceuticals

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings results on Thursday, May, 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.32. The company earned $4.83 million during the quarter, compared to analysts' expectations of $3.05 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 92.51% and a negative net margin of 462.00%.
View Syros Pharmaceuticals' earnings history

How has Syros Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYRS shares have increased by 9.1% and is now trading at $5.62.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SYRS?

6 brokerages have issued 12 month price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $13.00 to $20.00. On average, they expect Syros Pharmaceuticals' stock price to reach $17.00 in the next year. This suggests a possible upside of 202.5% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 60, Pay $1.03M)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 67, Pay $165k)
  • Dr. Eric R. Olson, Chief Scientific Officer (Age 63, Pay $696.42k)
  • Dr. David A. Roth, Chief Medical Officer (Age 58, Pay $713.03k)
  • Dr. James E. Bradner, Founder (Age 49)
  • Dr. Nathanael S. Gray Ph.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Joseph J. Ferra Jr., CFO & Treasurer (Age 45)
  • Mr. Gerald E. Quirk, Chief Legal & Admin. Officer and Sec. (Age 53)
  • Ms. Naomi Aoki, VP of Corp. Communications & Investor Relations
  • Dr. Christian C. Fritz, Head of Biology

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.47%), Sumitomo Mitsui Trust Holdings Inc. (8.38%), Nikko Asset Management Americas Inc. (8.18%), BlackRock Inc. (6.74%), Ally Bridge Group NY LLC (5.08%) and Orbimed Advisors LLC (2.97%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch.
View institutional ownership trends for Syros Pharmaceuticals

Which institutional investors are selling Syros Pharmaceuticals stock?

SYRS stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Millennium Management LLC, D. E. Shaw & Co. Inc., Dimensional Fund Advisors LP, Citigroup Inc., JPMorgan Chase & Co., Los Angeles Capital Management LLC, and Cubist Systematic Strategies LLC. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Eric R Olson, Richard A Young, and Srinivas Akkaraju.
View insider buying and selling activity for Syros Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Syros Pharmaceuticals stock?

SYRS stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., BlackRock Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Goldman Sachs Group Inc., Ally Bridge Group NY LLC, Morgan Stanley, and Orbimed Advisors LLC. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, and Mark J Alles.
View insider buying and selling activity for Syros Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $5.62.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals has a market capitalization of $347.64 million and generates $15.09 million in revenue each year. The company earns $-84,040,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

Syros Pharmaceuticals employs 103 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is

Where are Syros Pharmaceuticals' headquarters?

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.